X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Stem Cell Transplantation May Halt Course of MS Impairment

Content Team by Content Team
24th December 2022
in News, Research & Development

An Italian study that was recently published in Neurology, the official journal of the American Academy of Neurology, suggests that hematopoietic stem cell transplants may help persons having active secondary progressive multiple sclerosis (MS) delay disability.

The ten-year retrospective study comprised 1,975 MS drug-treated patients from the Italian MS registry and 79 active secondary progressive MS patients who underwent autologous hematopoietic stem cell transplantation.

For purposes of age, sex, and degree of handicap, the two groups were matched. Azathioprine, Beta-interferons, mitoxantrone, fingolimod, natalizumab, glatiramer acetate, methotrexate, teriflunomide, dimethyl fumarate, cyclophosphamide, and alemtuzumab were among the medications taken into consideration in the study. The Expanded Disability Status Scale was used to assess the participants’ level of disability. Participants had a median score of 6.5 at the beginning of the trial, which was defined as needing a walking stick or brace continuously on both sides to walk 20 metres without stopping.

Researchers showed that 62% of participants who received stem cell transplants did not have a worsening of their MS impairment five years after the procedure, versus 46% of those who took medication.

Furthermore, compared to just 4% of those receiving medication, 19% of individuals who underwent stem cell transplants had less disability at the end of the trial after five years.

The impairment score for those who underwent stem cell transplants fell by an average of 0.01 points annually over the course of ten years, indicating a lower level of disability. The average score for people who use medicine grew by 0.16 points annually, indicating a rise in impairment.

According to Dr. Matilde Inglese, the study’s author from the University of Genoa in Italy, this study reveals that hematopoietic stem cell transplantation is related to a slowdown in disability development and a higher potential for disability recovery compared to other therapies.

She continued, saying that while these results are hopeful, they are not applicable to secondary progressive MS patients who do not have evidence of inflammatory disease activity. She noted that more research in larger populations is required to support the findings.

The following were study limitations:

  • Since it was retroactive and observational, it cannot establish cause.
  • It excluded those receiving the MS medications rituximab, ofatumumab, ocrelizumab, siponimod, or cladribine.

The Italian Foundation for Multiple Sclerosis provided funding for the study.

Previous Post

Major Government Spending Bill Covers FDA, Research Issues

Next Post

Singapore Discovers Novel Diabetic Eye Disease Treatment

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Singapore Discovers Novel Diabetic Eye Disease Treatment

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In